Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  20.00 1.91% 1,066.00 3,584 10:30:10
Bid Price Offer Price High Price Low Price Open Price
1,066.00 1,074.00 1,080.00 1,018.00 1,018.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 86.39 12.63 20.00 53.3 528
Last Trade Time Trade Type Trade Size Trade Price Currency
10:30:10 AT 2 1,066.00 GBX

Ergomed (ERGO) Latest News

More Ergomed News
Ergomed Investors    Ergomed Takeover Rumours
Smart Money!
ERGO is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 

Ergomed (ERGO) Discussions and Chat

Ergomed Forums and Chat

Date Time Title Posts
10/6/202214:20Ergomed PLC998
14/1/202010:16Stephen Stamp, CFO of Ergomed (ERGO)2

Add a New Thread

Ergomed (ERGO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ergomed trades in real-time

Ergomed (ERGO) Top Chat Posts

Ergomed Daily Update: Ergomed Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ERGO. The last closing price for Ergomed was 1,046p.
Ergomed Plc has a 4 week average price of 925p and a 12 week average price of 925p.
The 1 year high share price is 1,585p while the 1 year low share price is currently 925p.
There are currently 49,507,129 shares in issue and the average daily traded volume is 292,522 shares. The market capitalisation of Ergomed Plc is £527,745,995.14.
km18: ...from last year... Company overview: Founded in 1997, Ergomed plc is a specialist services provider for the pharmaceutical industries, covering all phases of clinical development, post-approval pharmacovigilance and medical information. The company operates in more than 100 countries through its Pharmacovigilance and Clinical research Outsourcing service lines. The company has made several acquisitions over the past 5 years. Last three years’ performance is categorized by steady growth in Revenue, gross Profit and adjusted EBITDA and order book growth in 2020 of 55.5%. Acquisition in 2020 was in the USA with ambition to increase market presence for both business lines. Revenue in USA is currently accounting for around 54%, compared to UK’s 14% and EU area 27%. Latest update from the company shows strong trade with 38% growth in revenue in the first half of the year bringing the interim figure to £56m. CRO division generated a staggering 90.7%. Healthy balance sheet and prospects for growth are firmly supported by increase in cash balance to £24.6m and growth in order book at 18% since 01/01/2021....from WealthOracleAM
maddox: Hi Guys, I appreciate we're all a bit share shocked but this was an excellent trading update: >> Adjusted EBITDA ahead of mkt expectations (1) >> Revenue growth 37.3% (44.3% at constant currency) >> US very strong growth 59.5% (71% at constant currency) >> Throwing off cash. And the Outlook is positive - order book is up 24% and in value is twice 2021 revenue. So, conversion should ensure strong growth continues. Regards Maddox (1) I wish they would state a figure for 'market expectations' - it's public domain so why not?
whittler100: ERGO is an Ex-holding that did exceptionally well for me. However, in this market, I do question the PE valuation ascribed to the businesses by the market. I think that ERGO is a fine business but will wait until the next trading update before I reconsider taking a fresh position. I expect the next trading update to be in eh last week of this month.
walkernbudgie: This share is up and down like the whoares draws on boat race night
piedro: Edison Investment Research Lim Ergomed (ERGO): US is now the biggest market in the mix 4 October 2021 hTTps:// - US is now the biggest market in the mix - FX headwinds, but strong underlying growth - Margins also ‘masked’ by unfavourable FX rate - Valuation: £751m or 1,536p/share - H121 update: Operational momentum continues °° PrimeVigilance: Expanding to Japan °° CRO: Strong post-pandemic rebound continues
piedro: Ergomed@ErgomedPLC NEWS: We are delighted to share with both our customers and employees the new Ergomed Clinical Research website. It provides easier access to our solutions and services along with some integrated features and tools to assist in planning clinical trials. hTTps://
sharesoc: In case you missed our webinar with Ergomed the recording and stockopedia report can be found here: hxxps:// To access the recording, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps:// Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the recording (and recordings/reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://
etarip: See: hxxps://
blueflame: Disappointing to see the share price drift but with the TU due in the next week or so we should see the price rebound.
timbo003: I had assumed that the recent perkiness in the Ergo share price was due to them shifting away from the co-development model and just focusing on the pharmaceutical services parts of the business. Unfortunately I couldn't get to the AGM earlier this year, if I had gone, I had lots of questions about that. If they end up making the transition completely, I wonder if they are contemplating selling the future royalty streams from the current co-development portfolio? I suspect there would be plenty of potential buyers.
Ergomed share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220706 09:45:42